A detailed history of Calamos Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Calamos Advisors LLC holds 623,998 shares of BMY stock, worth $35.9 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
623,998
Previous 642,306 2.85%
Holding current value
$35.9 Million
Previous $26.7 Million 21.06%
% of portfolio
0.2%
Previous 0.17%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$39.66 - $51.75 $726,095 - $947,439
-18,308 Reduced 2.85%
623,998 $32.3 Million
Q2 2024

Jul 25, 2024

SELL
$40.25 - $52.99 $738,829 - $972,684
-18,356 Reduced 2.78%
642,306 $26.7 Million
Q1 2024

May 08, 2024

SELL
$47.98 - $54.4 $628,873 - $713,020
-13,107 Reduced 1.95%
660,662 $35.8 Million
Q4 2023

Jan 31, 2024

SELL
$48.48 - $57.85 $307,023 - $366,364
-6,333 Reduced 0.93%
673,769 $34.6 Million
Q3 2023

Oct 25, 2023

SELL
$57.89 - $64.73 $87,471 - $97,807
-1,511 Reduced 0.22%
680,102 $39.5 Million
Q2 2023

Jul 28, 2023

SELL
$63.71 - $70.74 $15.6 Million - $17.3 Million
-244,526 Reduced 26.4%
681,613 $43.6 Million
Q1 2023

May 03, 2023

SELL
$65.71 - $74.53 $6.63 Million - $7.52 Million
-100,851 Reduced 9.82%
926,139 $64.2 Million
Q4 2022

Jan 25, 2023

SELL
$68.48 - $81.09 $14.4 Million - $17.1 Million
-210,455 Reduced 17.01%
1,026,990 $0
Q3 2022

Oct 24, 2022

SELL
$0.13 - $76.84 $188 - $111,648
-1,453 Reduced 0.12%
1,237,445 $88 Million
Q2 2022

Aug 01, 2022

BUY
$72.62 - $79.98 $8.06 Million - $8.87 Million
110,934 Added 9.83%
1,238,898 $95.4 Million
Q1 2022

May 03, 2022

BUY
$61.48 - $73.72 $9.09 Million - $10.9 Million
147,888 Added 15.09%
1,127,964 $82.4 Million
Q4 2021

Feb 01, 2022

BUY
$53.63 - $62.52 $2.13 Million - $2.48 Million
39,711 Added 4.22%
980,076 $61.1 Million
Q3 2021

Oct 26, 2021

BUY
$59.17 - $69.31 $8.52 Million - $9.98 Million
143,994 Added 18.08%
940,365 $55.6 Million
Q2 2021

Jul 22, 2021

BUY
$61.91 - $67.42 $7.07 Million - $7.7 Million
114,232 Added 16.75%
796,371 $53.2 Million
Q1 2021

Apr 12, 2021

BUY
$59.34 - $66.74 $667,218 - $750,424
11,244 Added 1.68%
682,139 $43.1 Million
Q4 2020

Jan 27, 2021

SELL
$57.74 - $65.43 $1.1 Million - $1.24 Million
-18,983 Reduced 2.75%
670,895 $41.6 Million
Q3 2020

Oct 26, 2020

SELL
$57.43 - $63.64 $2.6 Million - $2.89 Million
-45,338 Reduced 6.17%
689,878 $41.6 Million
Q2 2020

Jul 27, 2020

BUY
$54.82 - $64.09 $5.1 Million - $5.96 Million
93,068 Added 14.49%
735,216 $43.2 Million
Q1 2020

Apr 28, 2020

SELL
$46.4 - $67.43 $1.48 Million - $2.15 Million
-31,818 Reduced 4.72%
642,148 $35.8 Million
Q4 2019

Jan 15, 2020

BUY
$49.21 - $64.19 $12.3 Million - $16 Million
249,074 Added 58.62%
673,966 $43.3 Million
Q3 2019

Oct 21, 2019

BUY
$42.77 - $50.71 $1.15 Million - $1.36 Million
26,910 Added 6.76%
424,892 $21.5 Million
Q2 2019

Aug 07, 2019

BUY
$44.62 - $49.34 $565,290 - $625,088
12,669 Added 3.29%
397,982 $18 Million
Q1 2019

Apr 12, 2019

BUY
$45.12 - $53.8 $109,190 - $130,196
2,420 Added 0.63%
385,313 $18.4 Million
Q4 2018

Jan 24, 2019

BUY
$48.76 - $63.23 $1.67 Million - $2.16 Million
34,234 Added 9.82%
382,893 $19.9 Million
Q3 2018

Oct 22, 2018

BUY
$55.19 - $62.25 $1.43 Million - $1.62 Million
25,996 Added 8.06%
348,659 $21.6 Million
Q2 2018

Jul 17, 2018

SELL
$50.53 - $62.98 $28.6 Million - $35.6 Million
-565,706 Reduced 63.68%
322,663 $17.9 Million
Q1 2018

Apr 13, 2018

SELL
$59.92 - $68.98 $981,249 - $1.13 Million
-16,376 Reduced 1.81%
888,369 $56.2 Million
Q4 2017

Feb 13, 2018

BUY
$59.94 - $65.35 $24.2 Million - $26.4 Million
403,665 Added 80.56%
904,745 $55.4 Million
Q3 2017

Oct 25, 2017

BUY
$55.23 - $63.74 $10.6 Million - $12.3 Million
192,255 Added 62.25%
501,080 $31.9 Million
Q2 2017

Aug 09, 2017

BUY
N/A
308,825
308,825 $17.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Calamos Advisors LLC Portfolio

Follow Calamos Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.